PT3

• Description :

  PT3 is a selective inhibitor of HDAC3 with an IC50 value of 0.25 μM. PT3 exhibits good brain penetration ability and bioavailability upon oral administration. PT3 can be used in the research of Alzheimer’s disease[1].

• UNSPSC :

  12352005

• Target :

  HDAC

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage; Epigenetics

• Applications :

  Metabolism-protein/nucleotide metabolism

• Field of Research :

  Metabolic Disease

• Purity :

  99.94

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C(C1=CN=C(NCC2=CC=CC=C2)C=N1)NC3=C(N)C=CC=C3

• Molecular Formula :

  C18H17N5O

• Molecular Weight :

  319.36

• References & Citations :

  [1]Sravani Pulya, et al. PT3: A Novel Benzamide Class Histone Deacetylase 3 Inhibitor Improves Learning and Memory in Novel Object Recognition Mouse Model. ACS Chem Neurosci. 2021 Mar 3;12 (5) :883-892.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• Isoform :

  HDAC1; HDAC2; HDAC8

• CAS Number :

  [2710273-81-5]